2Beyer DC, Puente F, Rogers KL, et al. Prostate brachy therapy: comparison of dose distribution with different 125Ⅰ source designs[J]. Radiology, 2001, 221 (3) :623.
3Ankem MK, DeCarvalho VS, Harangozo AM, et al. Implications of radioactive seed migration to the lungs after prostate brachytherapy[J]. Urology, 2002,59 (4): 555.
4Raben A, Mychalczak B. Brachy-therapy for non-small cell lung cancer and selected neoplasms of the chest[J]. Chest, 1997,112: 276s.
5Chen A, Galloway M, Landreneau R, et al. Intraopera tive 125Ⅰbrachytherapy for high-risk stage Ⅰ non-small cell lung carcinoma[J]. Int J Radiat Oncol Biol Phys,2000 ,6(4): 1083.
6Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000,92 (3) :205-216.
7McHugh K, Kao S. Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br J Radiol,2003,76(907): 433-436.
8James K, Eisenhauer E, Christian M, et al.Measuring response in solid tumors: unidimensional versus bidimensional measurement. J NatlCancerInst,1999,91(6): 523-528.
9Cortes J, Rodriguez J, Diaz-Gonzalez JA, et al. Comparison of unidimensional and bidimensional measurements in metastatic nonsmall cell lung cancer. Br J Cancer,2002,87(2): 158-160.
10Trillet-Lenoir V, Freyer G, Kaemmerlen P,et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol,2002,75(899): 903-908.
